571 related articles for article (PubMed ID: 11588134)
21. [Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
Liu JH; Li HW; Tong M; Li M; Na YQ
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):364-8. PubMed ID: 15061984
[TBL] [Abstract][Full Text] [Related]
22. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
23. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
24. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men.
Rajender S; Vijayalakshmi K; Pooja S; Madhavi S; Paul SF; Vettriselvi V; Shroff S; Singh L; Thangaraj K
J Androl; 2009; 30(6):703-10. PubMed ID: 19443907
[TBL] [Abstract][Full Text] [Related]
25. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
Scariano JK; Treat E; Alba F; Nelson H; Ness SA; Smith AY
Prostate; 2008 Dec; 68(16):1798-805. PubMed ID: 18780294
[TBL] [Abstract][Full Text] [Related]
26. Genetic variants of DNA repair genes and prostate cancer: a population-based study.
Ritchey JD; Huang WY; Chokkalingam AP; Gao YT; Deng J; Levine P; Stanczyk FZ; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1703-9. PubMed ID: 16030105
[TBL] [Abstract][Full Text] [Related]
27. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.
Ren Z; Cai Q; Shu XO; Cai H; Li C; Yu H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1290-5. PubMed ID: 15298948
[TBL] [Abstract][Full Text] [Related]
29. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
30. Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men.
Park K; Kim JH; Jeon HG; Byun SS; Lee E
Urology; 2010 Jun; 75(6):1516.e1-7. PubMed ID: 20350746
[TBL] [Abstract][Full Text] [Related]
31. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness.
Cicek MS; Nock NL; Li L; Conti DV; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1331-6. PubMed ID: 15298954
[TBL] [Abstract][Full Text] [Related]
32. TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
Bharaj B; Scorilas A; Giai M; Diamandis EP
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):387-93. PubMed ID: 10794483
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
Li X; Huang Y; Fu X; Chen C; Zhang D; Yan L; Xie Y; Mao Y; Li Y
Mutagenesis; 2011 May; 26(3):371-83. PubMed ID: 21177315
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in the 5alpha reductase type 2 gene and urologic measures of BPH.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; McGree ME; Hebbring SJ; Cunningham JM; Anderson SA; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2005 Mar; 62(4):380-7. PubMed ID: 15389785
[TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
38. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk.
Zheng W; Gao YT; Shu XO; Wen W; Cai Q; Dai Q; Smith JR
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):709-14. PubMed ID: 15159300
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D receptor polymorphisms and lethal prostate cancer.
Kibel AS; Isaacs SD; Isaacs WB; Bova GS
J Urol; 1998 Oct; 160(4):1405-9. PubMed ID: 9751364
[TBL] [Abstract][Full Text] [Related]
40. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]